Payment overview · 2025
General Payments
$160.24
4 reported records · 3 companies
Healthcare provider profile · identity verified
Teresa Cunningham, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · SPRINGFIELD, MO · NPI 1114401312
Verified facts
What the public records show
CMS Open Payments records show Teresa Cunningham, NP received $160.24 in general payments during 2025 across 4 reported records.
Inspire Medical Systems, Inc. accounted for 57.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $92.23 | 57.6% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $44.42 | 27.7% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $23.59 | 14.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $160.24 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $92.23 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $23.59 | 1 | 2025 |
Source payment records
|
|||||
| FABRAZYME Normalized: fabrazyme |
Biological | GENZYME CORPORATION | $21.33 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 480 | 122 |
| Atorvastatin Calcium | Atorvastatin Calcium | 328 | 86 |
| Amlodipine Besylate | Amlodipine Besylate | 299 | 83 |
| Gabapentin | Gabapentin | 295 | 74 |
| Lisinopril | Lisinopril | 290 | 82 |
| Losartan Potassium | Losartan Potassium | 257 | 62 |
| Omeprazole | Omeprazole | 249 | 65 |
| Metformin Hcl | Metformin Hcl | 211 | 55 |
| Metoprolol Succinate | Metoprolol Succinate | 192 | 54 |
| Simvastatin | Simvastatin | 192 | 54 |
| Carvedilol | Carvedilol | 170 | 43 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 164 | 48 |
| Pravastatin Sodium | Pravastatin Sodium | 163 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 161 | 39 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 153 | 44 |
| Potassium Chloride | Potassium Chloride | 150 | 47 |
| Trazodone Hcl | Trazodone Hcl | 143 | 37 |
| Tizanidine Hcl | Tizanidine Hcl | 135 | 35 |
| Sertraline Hcl | Sertraline Hcl | 129 | 32 |
| Meloxicam | Meloxicam | 121 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 119 | 37 |
| Montelukast Sodium | Montelukast Sodium | 116 | 29 |
| Pantoprazole Sodium | Pantoprazole Sodium | 104 | 24 |
| Famotidine | Famotidine | 98 | 22 |
| Furosemide | Furosemide | 95 | 25 |
| Buspirone Hcl | Buspirone Hcl | 92 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 86 | 21 |
| Eliquis | Apixaban | 83 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 81 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 79 | 23 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 78 | 14 |
| Tamsulosin Hcl | Tamsulosin Hcl | 77 | 18 |
| Glimepiride | Glimepiride | 73 | 23 |
| Metformin Hcl Er | Metformin Hcl | 73 | 23 |
| Atenolol | Atenolol | 68 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 61 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 61 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 61 | 11 |
| Allopurinol | Allopurinol | 58 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 58 | 16 |
| Prednisone | Prednisone | 57 | 45 |
| Spironolactone | Spironolactone | 57 | 18 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 53 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 52 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 50 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 48 | 11 |
| Januvia | Sitagliptin Phosphate | 47 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 44 | 13 |
| Lovastatin | Lovastatin | 42 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 41 | suppressed |
| Irbesartan | Irbesartan | 41 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 41 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 40 | 31 |
| Warfarin Sodium | Warfarin Sodium | 40 | suppressed |
| Ibuprofen | Ibuprofen | 39 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 39 | 12 |
| Xarelto | Rivaroxaban | 35 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 34 | suppressed |
| Topiramate | Topiramate | 33 | suppressed |
| Celecoxib | Celecoxib | 32 | suppressed |
| Memantine Hcl | Memantine Hcl | 32 | suppressed |
| Jardiance | Empagliflozin | 31 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 30 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 30 | suppressed |
| Baclofen | Baclofen | 28 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 28 | suppressed |
| Glipizide | Glipizide | 27 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 27 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 27 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 14 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Lamotrigine | Lamotrigine | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 18 |
| Doxazosin Mesylate | Doxazosin Mesylate | 22 | suppressed |
| Finasteride | Finasteride | 22 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 21 | suppressed |
| Ezetimibe | Ezetimibe | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 16 |
| Primidone | Primidone | 17 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 15 | 15 |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 15 |
| Silver Sulfadiazine | Silver Sulfadiazine | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Norgestimate-Ethinyl Estradiol | Norgestimate-Ethinyl Estradiol | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Ozempic | Semaglutide | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 13 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Humulin N Kwikpen | Insulin Nph Human Isophane | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $160.24 · 4 records | Inspire Medical Systems, Inc. | Dexcom G6 Transmitter, FABRAZYME, INSPIRE | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error